Cardiac Response to Chronic Intermittent Hypoxia with a Transition from Adaptation to Maladaptation: The Role of Hydrogen Peroxide by Yin, Xia et al.
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2012, Article ID 569520, 12 pages
doi:10.1155/2012/569520
Review Article
Cardiac Responseto Chronic Intermittent
Hypoxiawith a Transition fromAdaptation to Maladaptation:
TheRoleofHydrogenPeroxide
Xia Yin,1,2 Yang Zheng,1 QuanLiu,1 Jun Cai,2 andLuCai2
1The Cardiovascular Center, The First Hospital of Jilin University, Changchun 130021, China
2Department of Pediatrics, Kosair Children Hospital Research Institute, University of Louisville, Louisville, KY 40202, USA
Correspondence should be addressed to Yang Zheng, zhengyanghappy07@yahoo.com.cn and Lu Cai, l0cai001@louisville.edu
Received 7 February 2012; Accepted 20 March 2012
Academic Editor: Ivan Spasojevic
Copyright © 2012 Xia Yin et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Obstructive sleep apnea (OSA) is a highly prevalent respiratory disorder of sleep, and associated with chronic intermittent hypoxia
(CIH). Experimental evidence indicates that CIH is a unique physiological state with potentially “adaptive” and “maladaptive”
consequences for cardio-respiratory homeostasis. CIH is also a critical element accounting for most of cardiovascular
complications of OSA. Cardiac response to CIH is time-dependent, showing a transition from cardiac compensative (such
as hypertrophy) to decompensating changes (such as failure). CIH-provoked mild and transient oxidative stress can induce
adaptation, but severe and persistent oxidative stress may provoke maladaptation. Hydrogen peroxide as one of major reactive
oxygen species plays an important role in the transition of adaptive to maladaptive response to OSA-associated CIH. This
may account for the fact that although oxidative stress has been recognized as a driver of cardiac disease progression, clinical
interventionswithantioxidantshavehadlittleornoimpactonheartdiseaseandprogression.Herewefocusontheroleofhydrogen
peroxide in CIH and OSA, trying to outline the potential of antioxidative therapy in preventing CIH-induced cardiac damage.
1.Introduction
Obstructive sleep apnea (OSA) is a highly prevalent respi-
ratory disorder of sleep, characterized by recurrent episodes
of complete or partial upper airway obstruction. It may
develop at diﬀerent ages from the premature infant to the
elderly, with a prevalence related to age and sex, increasing
signiﬁcantly in the elderly (5–9%) [24]. The prevalence of
OSAin children is generally1–3% [25] and even higher (e.g.,
5-6%) in certain conditions [26]. The prevalence of OSA
in the general population of adult men and women is 3–
7% and 2–5%, respectively [27, 28] and keeps increasing in
the elders [24]. OSA was often found in the patients with
diabetes and obesity since it is involved in the development
ofinsulinresistance,glucoseintolerance,type2diabetes,and
metabolic syndrome independently of adiposity [29–32].
OSA was also considered as a causal factor in cardiovascular
diseases [33, 34].
Collapsibility of the upper airway during sleep can be
increased by underlying anatomical alteration and/or dis-
turbances in upper airway neuromuscular control, both
of which play key roles in the pathogenesis of OSA [35].
OSA-induced recurrent episodes of complete or partial
collapse of the upper airway during sleep are associated
with reductions in ventilation, which often leads to repetitive
apneas and hypopneas. Each of these obstructive respiratory
eventsresultsinrecurrentepisodeofhypoxia.Reoxygenation
occurs when the episode is terminated by an arousal that
restores the airway patency. The recurrence of these hypoxia
and reoxygenation episodes produces a characteristic pattern
of nocturnal intermittent hypoxia that is unique to OSA.
Generally, both apneas and hypopneas events can produce
the same pattern of chronic intermittent hypoxia (CIH),
sleep arousals also called sleep fragmentation, hemodynamic
changes [36–38], and symptoms of disruptive snoring and
daytime sleepiness. Clinical consequences of the disorder2 Oxidative Medicine and Cellular Longevity
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Figure 1: OSA-induced cardiovascular diseases. OSA increases the risk of cardiovascular diseases through three main pathological processes
related with OSA: chronic intermittent hypoxia (CIH), sleep fragmentation (SF), and intrathoracic pressure changes. It can increase the risk
of heart failure by 140%, stroke by 60%, and coronary heart disease by 30%. It can also increase the risk of other cardiovascular diseases such
as hypertension and cardiac arrhythmia.
cover a wide spectrum, including daytime hypersomno-
lence, neurocognitive dysfunction, cardiovascular disease,
metabolic dysfunction, and corpulmonale [37].
It has been recognized that OSA is a potential life-
threatening condition and has become one of the most com-
mon public health problems [39, 40]. Since OSA is emerging
as a cardiovascular risk factor, it became an important
target for public health interventions aiming at reducing
cardiovascular diseases [41].
Mammalian heart is an obligate aerobic organ and a
constant supply of oxygen is indispensable for cardiac vi-
ability and function [42]. The heart as a contractile pump
has the highest O2 consumption among all body organs,
which can be increased eight-fold or more under maximal
workload conditions [43]. Consequently, cardiac tissue is
susceptible to lack of O2 and also highly dependent on
oxidative metabolism to maintain its normal function [44].
Since CIH is one of the main events of OSA, OSA has been
considered as an independent risk factor for cardiovascular
morbidity [41, 45–47], such cardiovascular diseases includ-
ing hypertension [45–53], stroke [54] ,a n de v e ng l u c o s e
metabolic abnormality [55], and so forth. For instance, it has
been reported that OSA can increase the risk of heart failure
(HF) by 140%, stroke by 60%, and coronary heart disease by
30% [56].
As outlined in Figure 1, three major components of OSA
associated with cardiovascular events are large swings in
intrathoracic pressure, postapneic arousals, and CIH [57].
A body of experimental evidence has indicated that CIH
is a unique physiological state with a proﬁle of biological
consequences distinct from other types of hypoxia [46, 47,
51]. In Figure 1, the negative cardiovascular consequences of
OSA are illustrated, all of which were considered critically
related to the unique pattern of CIH [38, 52, 53, 58]. In
this paper, therefore, we would like to summarize the several
features of CIH-induced cardiac changes at the early and
later stages, based on both epidemiological and experimental
animal information.
2. CardiacResponse to CIH:ATransition
from Adaptation to Maladaptation
It has been reported that innate defense systems (adaptation)
that are induced by exposure to repeated and relatively brief
episodes of hypoxia act as a powerful temporal protective
phenomenon [59]. Adaptation to chronic hypoxia was
also reported to increase cardiac tolerance to all major
deleteriousconsequencesofacuteoxygendeprivationsuchas
myocardial infarction, contractile dysfunction, and ventricu-
lar arrhythmias [60]. However, long-term exposure to CIH
may be detrimental to cardiac function (maladaptation).
OSA exposes the cardiovascular system to CIH, oxidative
stress, and systemic inﬂammation. With the extension of
exposure duration to CIH, these factors can compel the
heart to induce a transition from cardiac compensative (such
as cardiac hypertrophy) to decompensative change (such
as HF), that is, a transition from cardiac adaptation to
cardiac maladaptation. OSA-related CIH has been suggested
to play the main role in the development of left ventricularOxidative Medicine and Cellular Longevity 3
Table 1: The eﬀects of CIH on cardiac I/R-induced injuries.
Authors Strains Exposure time Eﬀects Reference
Wang et al. Male SD rats 4wks Protective eﬀects [1]
Ding et al Male SD rats 42 days Protective eﬀects [2–4]
Neckar et al. Male Wistar rats 8h/day, 5 days/wks; Protective eﬀects [5]
Asemu et al. Male Wistar rats 2 wks and 5wks Protective eﬀects [6]
Park and Suzuki C57BL/6 mice 1, 2 wks and 4 wks Protective eﬀects (4 wks)
Deleterious eﬀects (1, 2wks) [7]
Guo et al. male guinea pigs 28 days Protective eﬀects [8]
Guo et al. Male guinea pigs 28 days Protective eﬀects [9]
Zong et al. Dogs 20 days Protective eﬀects [10]
Wang et al. Male SD rats 14, 28 and 42 days Protective eﬀects [11–13]
Joyeux-Faure et al. Male Wistar rats 7wks Deleterious eﬀects [14]
∗wks: weeks.
remodeling including cardiac hypertrophy, cardiac ﬁbrosis,
and cardiac dysfunction [61, 62]. This transition can impair
myocardial contractility and cause development and pro-
gression of HF [63].
2.1. Cardiac Adaptation to CIH
2.1.1. CIH Eﬀectively Protects the Heart against Ischemia/Re-
perfusion or Hypoxia/Reoxygenation-Induced Injury. It is re-
ported that CIH can induce preconditioning-like eﬀect to
eﬀectively protect the heart against ischemia/reperfusion
(I/R) or hypoxia/reoxygenation-induced injury [1–6, 8–11,
64, 65], including the prevention of I/R-induced cardiac
apoptosis and necrosis [3, 5] arrhythmias [6]. CIH also can
improve postischemic recovery of cardiac function [1].
For instance, Park and Suzuki exposed C57BL/6 mice
to CIH for 1, 2, and 4 weeks and then observed the eﬀect
on I/R injury. Results demonstrated that CIH exposure for
1-2 weeks resulted in increased susceptibility of the heart
to I/R injury, while the heart appeared to adapt to CIH
for 4 weeks by normalizing its susceptibility to I/R injury
[7]. Their results imply that heart also has the ability to
adapt to the condition of the CIH-mediated enhancement
of the susceptibility to I/R. Guo et al. found that although
cardiac hypertrophy may not occur in the right and left
ventricles, the adaptation of guinea pigs to CIH signiﬁcantly
increased cardiac tolerance to I/R, shown by an improved
recovery of contractile function, an increased coronary ﬂow
a n dar e d u c e dl e v e lo fr e a c t i v eo x y g e ns p e c i e s( R O S )i n
cardiomyocytes [9]. These results are consistent with those
observed in dogs and rats [4, 10, 11]. These data clearly show
that CIH-induced cardiac protection against I/R-induced
injury universally exists in diﬀerent strains of animal models.
CIH can promote recovery of cardiac contractile function
from I/R, limiting cardiac infarction and arrhythmia caused
by I/R [10, 12, 13]. Table 1 presents a summary of the
protective eﬀect of CIH on cardiac I/R-induced injuries.
It seems that extensive cardiac protection by short-term
CIH (less than 6 weeks) may be very similar to ischemic
preconditioning, most likely sharing common signaling
pathways [66].
2.1.2. CIH Induces Compensatory Increase of Cardiac Func-
tion. Naghshin et al. [15] exposed C57BL/6J mice to CIH for
4weeksandthenassessedcardiacfunctionbyechocardiogra-
phy and pressure-volume loop analyses. They found that left
ventricular(LV)ejectionfraction(LVEF)andothermeasures
of LV contractility were increased in CIH-exposed animals
compared to controls. There was no change in contractile
proteins, atrial natriuretic peptide levels, LV posterior wall
thickness, or heart weight following the exposure to CIH.
These results indicated that there was a compensatory in-
crease in LV cardiac contractility that occurred independent
ofventricularhypertrophyinthemousemodelofCIH.Ithas
been proposed that this adaptation, at least in part, results
from activation of cardiac β-adrenergic pathways [15].
Lee et al. [16] showed that short-term IH (for 1 and 4 days)
has protective eﬀects on the heart. Campen et al. [17]f o u n d
that CIH has produced a 26% increase in right ventricle
weight and 10% increase in LV + septum weight, resulting
in a signiﬁcant increase by14% of the right ventricle/LV +
septum ratio. Table 2 summarized previous studies available
intheliterature,whichshowedthatcardiachypertrophymay
initiallyrepresentanadaptiveresponse,butwiththeextentof
exposure time, the hypertrophy ultimately is responsible for
ventriculardilatationandHF.Theseresultssuggestthatthere
is transition for cardiac response to CIH from adaptation to
maladaptation.
2.2. Cardiac Maladaptation to CIH
2.2.1. CIH Enhances Cardiac Susceptibility to I/R-Induced
Injury. While short-term CIH was found to elicit a pre-
conditioning-like events [2, 3, 67], Joyeux-Faure et al. [14]
reported that CIH increased the heart susceptibility to I/R-
induced injury. They exposed Wistar male rats to CIH
for 7 weeks and then exposed the heart to ischemia and
reperfusion for 30 and 120min. Cardiac infarct sizes were
found to be signiﬁcantly higher in CIH group in comparison
to the control group. This was the ﬁrst study to show
that CIH makes the heart more sensitive to I/R injury
and suggested that although short-period exposure to CIH
can stimulate protective mechanism to reduce subsequent4 Oxidative Medicine and Cellular Longevity
Table 2: Eﬀect of CIH on cardiac functions.
Authors Strains Exposure time Eﬀects Reference
Naghshin et al. C57BL/6J mice 4 wks Protective eﬀects [15]
Lee et al. SD rats 1, 4 days and 1, 2wks 1, 4 days: protective eﬀects
1, 2 wks: deleterious eﬀects [16]
Campen et al. C57BL/6J mice Deleterious eﬀects [17]
Chen et al. Male SD rats 5wks Deleterious eﬀects [18, 19]
Williams et al. Male SD rats 5wks, 6wks Deleterious eﬀects [20]
Chen et al. Male SD rats 10 days Deleterious eﬀects [21]
Yin et al. FVB mice 4wks and 8wks Deleterious eﬀects [22]
Yang et al. Patients 4wks and 8wks Deleterious eﬀects [23]
∗wks: weeks.
lethal I/R-induced injury as discussed above, prolonged
CIH beyond protective periods might turn to a condition
with increased susceptibility to oxidative stress such as I/R-
induced cardiac injury (Table 1).
2.2.2. CIH-Induced Cardiac Dysfunction. Similar to hypoxia-
provoked maladaptive consequences on cardiorespiratory
homeostasis [68–70], long-term exposure to CIH may
decrease cardiac functions [18, 19]. OSA-induced CIH and
hypercapnia are related to continuous changes in pulmonary
volume, intrathoracic pressure, and microarousals. These
repetitions of respiratory events and rapid changes in
alertness are the main reasons why OSA induces acute
hemodynamic modiﬁcations, including the heart rate, blood
pressure, and cardiac output. In addition, CIH also con-
tributes, in the long run, to an increase in autonomous ner-
vous system drive, generation of ROS, endothelial dysfunc-
tion, and metabolic abnormalities, which in turn increase
both the blood pressure and the cardiovascular risks [71].
Short-term changes of hemodynamic parameters include
hypoxia, hypercapnia, negative intrathoracic pressure, and
microarousal, while long-term changes of hemodynamic
parameters include sympathetic activity, metabolic and hor-
monal changes, oxidative stress, inﬂammation, endothelial
dysfunction, hypercoagulability, and genetic eﬀects [71].
Rodent models of CIH exposure lasting from days to
weeks have exhibited multiple adverse outcomes, including
hypertension [17, 72], insulin resistance [73, 74], hyper-
lipidemia [75], atherosclerosis [76], and increased size of
experimentally induced cardiac infarction [7, 14]. In rats,
CIH leads to several cardiovascular consequences that are
also observed in human OSA, including blood pressure
elevation, biventricular hypertrophy, and LV contractile
dysfunction [18–20, 53]. These data suggest that CIH
exposure is detrimental to many physiological processes.
Accumulating data indicate that CIH can induce cardiac
dysfunction as its maladaptation [18, 19, 21]. Several studies
have focused on the point that CIH induces cardiac dys-
function, but conclusions were inconsistent. Lee et al. [16]
showed that short-term CIH exposure of rats for 1 and
4 days appeared to exert protective eﬀects on the hearts,
whereas long-term CIH exposure for 1 and 2 weeks appeared
to exert deleterious eﬀects. Williams et al. also used rats
to conﬁrm that after exposure to CIH for 10 days, cardiac
function was decreased [20]. Fagan reported that treatment
of CB57BL/6J mice with 2 min cycles of 10% alternating
with 21% oxygen for 8h per day for 4 weeks increased
right ventricular systolic pressure, right ventricular mass,
and neovascularization of distal pulmonary vessels, but had
no eﬀect on LV mass [77]. Campen and coworkers [17]
reported that CB57BL/6J mice exposed to a 5-week regimen
of 60-second cycles of 21% alternating with 5% oxygen
for 12h per day did develop signiﬁcant increases in both
systemic and pulmonary vascular pressures showing more
prominent right than LV hypertrophy. Chen’s group exposed
male Sprague-Dawley rats to CIH for 4 and 8 weeks and
found that abnormal myocardial architecture and increased
interstitial space were observed after 4 weeks and became
m o r eo b v i o u sa t8w e e k s[ 21]. In addition, a decreased ratio
of wall thickness to cavity diameter and cardiac dilatation
were observed after 8 weeks. They have proposed that a
longer duration of CIH could induce abnormal myocardial
architecture and even lead to the transition from eccentric
cardiac hypertrophy to dilated cardiac hypertrophy. In our
own study, we used 8–10-week-old FVB mice for exposure to
CIH for 4 and 8 weeks. Exposure to CIH for 4 weeks induced
cardiac hypertrophy, cardiac ﬁbrosis, cardiac inﬂammation,
and even cardiac dysfunction. Beside the above changes,
exposure to CIH for 8 weeks induced cardiac apoptosis,
oxidative stress and damage along with cardiac dysfunction,
showing progressive pathological changes [22].
The diversity of observations among diﬀerent research
groups implies that the diﬀerence of cardiac responses to
CIH may be related to many factors: (1) diﬀerent resistance
to hypoxia of diﬀerent animals [15, 16, 21, 77]; (2) age of
the animals that were used for starting the experiments; (3)
the diﬀerent protocols of CIH (including oxygen level, cycle
length, number of hypoxic episodes per day, and number
of exposure days, etc.). For example, Zhang et al. [78]h a v e
exposed postnatal male Sprague-Dawley rats to intermittent
hypobaric hypoxia (IHH) at 3000m high-altitude (PB =
525mmHg, PO2 = 108.8mmHg) or at 5000m high-altitude
(PB = 404mmHg,PO2 = 84mmHg),andshamcontrol,and
then perfused the isolated hearts in the Langendorﬀ system
with 30min. global ischemia and 60min. reperfusion. They
found that the recovery of cardiac function was enhanced,Oxidative Medicine and Cellular Longevity 5
coronary ﬂow was increased and lactate dehydrogenase
activity was decreased in 3000m-IHH group at 60min after
I/R. In addition, cardiac function restored better in 3000m-
IHH group after 42 days of IHH than that after 28 days
of IHH. In contrast to the above, the recovery of cardiac
function was lower, coronary ﬂow was decreased, and lactate
dehydrogenase activity was increased in 5000m-IHH group.
The results suggest that the eﬀect of CIH on I/R could
be aﬀected by the modes of IH exposure. In addition, the
duration of CIH was the key determinant for the diﬀerent
eﬀects on the I/R-induced cardiac damages and functional
changes [15, 17, 21].
Although there are some diﬀerences of CIH-induced
cardiac functional changes among animal models, Yang et
al. [23] have examined the cardiac function of OSA patients
with echocardiogram and found that the LVEF, fractional
shortening (FS), and the ratio of early-to-late diastolic ﬁlling
in patients with severe OSA was lower than in those with
moderate OSA and in healthy controls. The inner diameters
of the main pulmonary artery and right ventricle as well
as the thickness of anterior wall of the right ventricle
were increased in patients with severe OSA compared to
those with moderate disease, which was worsened as a
function of time with disease. The tissue Doppler imaging-
derived Tei index and pulmonary artery systolic pressure
were also increased along with the severity of OSA. LVEF
and FS in patients who had suﬀered from OSA over 10
years were decreased compared to those suﬀering from
OSA for a shorter time. LVEF and FS in patients with
secondary hypertension were decreased signiﬁcantly relative
to nonhypertensive OSA patients and healthy controls. The
ratio of early-to-late diastolic ﬁlling was decreased in OSA
patients whether they had secondary hypertension or not.
These results suggest that OSA aﬀects the LV diastolic
function in the early stage of the disease. Extended exposure
to OSA resulted in LV systolic dysfunction with increased
hypertension. Right ventricle dysfunction and abnormalities
became more severe as the disease progressed. The results
conﬁrm the conclusion from clinical data that the duration
of OSA is the key factor for OSA-induced cardiac damage.
HF is frequently observed in OSA patients, with a preva-
lence of 11–37% [79, 80]. Data obtained in the Sleep Heart
Health Study have shown a 2.38 times increased likelihood
of having HF in association with OSA, independent of other
risk factors. OSA is not only a consequence of HF but indeed
represents a risk factor for this condition [81], independent
of hypertension [82]. Several grades of cardiac alterations
havebeenreportedinOSApatients,fromsilentorsubclinical
echocardiographic LV abnormalities to symptomatic systolic
dysfunction (Table 2).
Based on the above discussion, we propose that the
longer exposure to OSA-relevant CIH, the worse of the
cardiac dysfunction. With the extension of exposure time to
CIH, cardiac functions transit from compensative to decom-
pensative phase as from cardiac hypertrophy to cardiac
dilation even cardiac failure at the end. The development
of contractile dysfunction is an important feature of cardiac
decompensation (maladaptation) during CIH exposure to
stressandalsoahallmarkofadversecardiacremodeling[83].
3. OxidativeStress Isthe Predominant
Mechanismof CardiacResponse to CIH:
Role of Hydrogen Peroxide
Although OSA has been implicated in the pathogenesis
of various cardiovascular diseases, mechanisms by which
OSA aﬀects the cardiovascular system are largely unknown.
Oxidative stress, endothelial dysfunction, and inﬂammation
are long-term consequences that mediate cardiovascular
disease in patients with OSA [38]. Now, numerous studies
have shown that oxidative stress is the main mechanism
of cardiac I/R injury [84–86]. Because there is resemblance
between the patterns of CIH associated with OSA and I/R
injury, potential mechanisms of oxidative stress in OSA have
been postulated to be related directly to CIH in a manner
similar to I/R injury or indirectly via inﬂammatory response.
The increased sympathetic tone and elevated catecholamine
levelmightalsobeassociatedwithincreasedROSproduction
[38]. Most recent studies in patients with OSA and animal
models of CIH conﬁrm that OSA is associated with oxidative
stress, which generally correlates with the severity of sleep
apnea, and improves with treatment [38, 87].
Oxidative stress represents an imbalance between the
production of ROS and the antioxidant capacity of a bio-
logical system to buﬀer ROS. On the other hand, ROS are
involved in signaling cascades, so that subphysiological ROS
production may lead to reductive stress which has recently
also been suggested to be detrimental in certain cardiac
conditions [43, 88]. A ﬁne balance between redox state and
metabolism is more important than oxidative stress itself,
and an imbalance in either the oxidative or the reductive
direction could be detrimental [43]. In the past, ROS were
considered solely injurious, but now it is generally accepted
that they may exert both deleterious and beneﬁcial actions
[89]. In the last decade, they were consistently described as
regulators of signal transduction and as second messengers
in many signaling pathways in all cells that mediate cardio-
protection [90–93]. The data of Kolar and Ostadel suggest
that ROS not only contribute to I/R injury in normoxic rat
hearts, but also are involved in the protective mechanisms
induced by CIH [60]. During adaptation to CIH, repetitive
cycles of hypoxia and reoxygenation (sublethal stresses) may
lead to the production of ROS in the hypoxic heart, and
the latter trigger a cascade of events that lead to increased
antioxidant enzyme activity. These ﬁndings indicate that the
ROS produced in cardiac tissue during sub-lethal stress may
participate and activate signal transduction pathways [94]
that form a positive feedback loop consisting of ROS and
transcriptional factors [95]. This kind of strictly regulated
generation of ROS at low levels can mediate physiological
functions, such as increased level of antioxidative protection
(enzymatic and nonenzymatic), growth, diﬀerentiation, and
metabolismincardiomyocytes[42,96].Itmaybeinvolvedin
potentially adaptive processes such as adaptation to hypoxia
andmodulationofexcitation—contractioncoupling.Onthe
other hand, the generation of higher levels of ROS and/or
more potent oxidants such as hydroxyl radical may result in
pathological changes as a result of macromolecular damage6 Oxidative Medicine and Cellular Longevity
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as well as inadequate signaling [43]. It is important to note
that in addition to ROS, reactive nitrogen species, such as
nitric oxide, play crucial roles in the regulation of cardiac
functions. The metabolism of reactive nitrogen species is
intertwined with ROS.
Sources of ROS and RNS in cardiomyocytes include
mitochondria [97, 98], NADPH oxidase [99, 100], xanthine
oxidase [101, 102] and uncoupled nitric oxide synthases
[103, 104]. ROS include superoxide radical anion, hydroxyl
radical, and hydrogen peroxide (H2O2). The superoxide is a
relatively nonreactive, particularly targeting metalloproteins.
It can be dismutated to H2O2 by superoxide dismutase. ROS
exerts biological eﬀects either by causing nonspeciﬁc oxida-
tive damage to DNA, proteins, lipids, and macromolecules
orthroughspeciﬁcmodulationofcellularsignalingpathways
(redox signaling). Cellular levels of ROS and their eﬀects are
regulated by a variety of speciﬁc and antioxidant systems
(e.g., catalase, superoxide dismutase, glutathione peroxidase,
peroxiredoxin, thioredoxin, and various vitamins) [105].
H2O2 ismembranepermeableanddiﬀusible,lessreactive
and longer-lived than hydroxyl radical or superoxide radical
anion, and it is best suited for intra- and even inter-cellular
signaling [106]. The physiological range of intracellular
H2O2 concentrations appears to be remarkably conserved
in diﬀerent forms of life [107]. Among ROS, H2O2 is the
only species that is generated and removed by several speciﬁc
enzymes, which suggests that the intracellular concentra-
tion of H2O2 is tightly regulated and may serve speciﬁc
cellular functions. Superoxide dismutase can catalyze the
dismutationofthesuperoxideradicaltoH2O2 andmolecular
oxygen. Then it can be converted to H2O by catalase
and glutathione peroxidase (Figure 2). H2O2 may react
with transition metals, such as iron or copper to produce
the highly reactive hydroxyl radical. In living organisms,
besides its well-known cytotoxic eﬀects, H2O2 also plays an
essential role as a signaling molecule in regulating diverse
biological processes such as immune cell activation, vascular
remodeling, and apoptosis [108–110].
AlthoughH2O2 cancontributetoI/Rinjury,itappearsto
play the part of activator in processes in which CIH upregu-
lates the antioxidant enzymes. Using a cultured chick embry-
onic cardiomyocyte H/R model, Zhang et al. demonstrated
that H2O2 is involved in ischemic preconditioning [111].
Preconditioning protects ischemic cardiomyocytes through
H2O2 by opening mitochondrial K-ATP channels via acti-
vating PKC-ε pathway [111]. Park and Suzuki presented evi-
dencethataredoxregulator,thioredoxin,whichcanscavenge
H2O2,isupregulatedinadaptedheartsinresponsetoI/Rand
downregulated in the heart showing increased susceptibility
to I/R following 2 weeks of CIH [7]. Their results suggested
that thioredoxin plays a role in this adaptive mechanism as a
scavenger of H2O2 and also represent a proof about H2O2’s
role in cardiac maladaptation. The Janus character of H2O2
as a mediator of growth and apoptosis suggests speciﬁcity of
its biological activity. A number of studies have illustrated
that, at concentrations in the high physiological range, H2O2
induces adaptive changes, increasing resistance of biological
systems not only to oxidative stress but also to many other
stimuli [43, 106]. The capability of H2O2 to induce a large
number of protein syntheses and to provide cross-resistance
implies that living systems may “intentionally” produce
H2O2 as a component of adaptation in response to diﬀerent
ﬂuctuationsandperturbationsshiftingthesystemawayfrom
homeostasis. However, if the concentration of H2O2 exceedsOxidative Medicine and Cellular Longevity 7
the physiological concentration or the stress persists for a
longer period of time, it can induce cardiac maladaptation.
Thus, H2O2 is an important ROS in the transition of cardiac
response to CIH from the adaptive phase to maladaptive
phase or from cardiac hypertrophy to cardiac failure.
As H2O2 is generated by many compartmentalized en-
zymes, local variations in the concentration of H2O2 could
also be crucial for the activation of speciﬁc targets [110].
Treatment of diﬀerent primary cells with increasing doses of
exogenous H2O2 induces proliferation, senescence, or apop-
tosis. Studies using other experimental models also showed
H2O2 as a ROS having a ﬂag potential for adjustments
related to hypertrophy and/or cell death depending on its
intracellular concentration [112, 113].
4.Effects of Antioxidantson the
CIH-InducedCardiacResponse
OSA is recognized as an oxidative stress-related disorder
[114]. In addition, the concept that oxidative stress resulting
from an imbalance between increased ROS generation and
inadequate endogenous antioxidant pools contributing to
HF is well established [43]. Therefore, agents able to abolish
oxidative stress are attractive for prophylactic and therapeu-
tic intervention of OSA. Antioxidant pharmacotherapy for
OSA is considered as a viable and attractive clinical option,
especially in the light of poor compliance of continuous
positive airway pressure—the gold standard treatment for
OSA.
Understanding of complex actions of CIH, which can
exert both protective and detrimental eﬀects, may reveal
important information for developing therapeutic strategies
for a better management for OSA patients [7]. Cardiac
response to CIH should help developing therapeutic strate-
gies to prevent and/or treat OSA-induced cardiovascular
complications. A number of studies have been conducted
using CIH-treated animal models to explore the eﬀects
of antioxidants, but the outcomes of these studies are
controversial.
InthestudyofSkellyetal.[115],tempol(1mM,superox-
ide dismutase mimetic) was applied in the treatment of rats
exposedtoCIH.Itwasfoundthatantioxidanttreatmentmay
bebeneﬁcialasanadjunctOSAtherapy.Doehneretal.found
that allopurinol, a xanthine oxidase inhibitor, free radical
scavenger, and lipid peroxidation inhibitor [116], was asso-
ciated with the improvement of CIH-related oxidant stress,
cardiac dysfunction, and apoptosis in rats [20]. However,
Kolor and coworkers demonstrated that the pretreatment
of antioxidant N-acetylcysteine completely prevented the
development of cardioprotection in CIH rats although the
infarct size was reduced [117]. This clearly implies the
dual roles, adaptive and maladaptive, of ROS in CIH. The
suppression of ROS production prior to hypoxia prevented
the adaptive responses to be activated, but on the other
hand, on the long run, it showed positive eﬀects on cardiac
function. Inamoto et al. [118] conﬁrmed in their study using
CIH-treated mice model that pitavastatin preserved, at least
partially, the morphological structure of the LV myocardium
in lean mice exposed to CIH, through its antioxidant eﬀect.
Unlike in the acute experiment, a chronic antioxidative
treatment with N-acetylcysteine during the adaptation to
hypoxia led to a signiﬁcant attenuation of the improvement
in tolerance to lethal myocardial injury. Generally, the dual
eﬀects might, at least partially, explain why clinical trials
with antioxidants failed to conﬁrm promising data obtained
in a number of animal studies. It is obvious that beneﬁcial
consequences of antioxidant supplementation in normal
healthy heart cannot be used to predict an outcome in
adapted or diseased hearts [117].
In clinical studies, the results of antioxidants treatments
were also inconsistent. From a clinical perspective, much
attention has focused on the concept that oxidative stress
may be a driver of cardiac disease progression (e.g., HF), but
clinical interventions with antioxidants have had little or no
impact on heart disease risk and progression [43]. Results
of relatively few controlled clinical trials with antioxidants
such as vitamin C, α-tocopherol (vitamin E), and coenzyme
Q10 are also controversial [119, 120]. Oral N-acetylcysteine
administration appears to have a therapeutic potential in the
treatment of OSA. It is proposed that long-term treatment
with N-acetylcysteine in patients with OSA may reduce their
dependency on continuous positive airway pressure therapy
[121].
5. Prospective
Excessive oxidative stress undoubtedly exerts toxic and
detrimental eﬀects through modiﬁcation of biomolecules
or triggering damaging signals and also plays important
roles in the pathogenesis of certain oxidative stress-related
diseases, such as OSA-elicited cardiac dysfunction. Thus,
supplementation of exogenous antioxidants may be used
to balance cellular redox status. However, low levels of
R O Ss u c ha sH 2O2 also function as signal molecules and
induce adaptive response to protect the cells. Under such
condition, we may not supply exogenous antioxidants since
they may attenuate or completely block the adaptive signals,
as proposed in a recent review [122]. Antioxidants may
be considered at higher H2O2 concentrations related to
pronounced oxidative damage, but if applied too early
they may interfere with adaptive processes. However, the
threshold of H2O2 or other ROS associated with a switch
from mild/transient to severe/persistent oxidative stress has
not yet been identiﬁed in OSA patients or OSA-relevant CIH
models with cardiac dysfunction, which could be a good
molecular diagnosis and/or monitoring in the development
and progression of this disorder. Nevertheless, the concept
of cardiac response to chronic intermittent hypoxia with a
transition from adaptation to maladaptation will help us
to understand the pathogenic mechanisms of OSA-induced
cardiac damage and shed light on potential prevention
and therapy. Since OSA is considered as a life-threatening
conditionandasanindependentriskfactorofcardiovascular
diseases, we anticipate an intervention of eﬀective exogenous
antioxidantsand/orinductionofendogenousantioxidantsin
heart at the right time and proper dose may have protective
eﬀect against OSA-induced cardiac damage.8 Oxidative Medicine and Cellular Longevity
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